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Abstract
Objective—Flow cytometry (FC) is a widely acknowledged technology in diagnosis of acute 
myeloid leukemia (AML) and has been indispensable in determining progression of the disease. 
Although FC plays a key role as a post-therapy prognosticator and evaluator of therapeutic 
efficacy, the manual analysis of cytometry data is a barrier to optimization of reproducibility and 
objectivity. This study investigates the utility of our recently introduced non-parametric Bayesian 
framework in accurately predicting the direction of change in disease progression in AML patients 
using FC data.
Methods—The highly flexible non-parametric Bayesian model based on the infinite mixture of 
infinite Gaussian mixtures is used for jointly modeling data from multiple FC samples to 
automatically identify functionally distinct cell populations and their local realizations. Phenotype 
vectors are obtained by characterizing each sample by the proportions of recovered cell 
populations, which are in turn used to predict the direction of change in disease progression for 
each patient.
Results—We used 200 diseased and non-diseased immunophenotypic panels for training and 
tested the system with 36 additional AML cases collected at multiple time points. The proposed 
framework identified the change in direction of disease progression with accuracies of 90% (9 out 
of 10) for relapsing cases and 100% (26 out of 26) for the remaining cases.
Conclusions—We believe that these promising results are an important first step towards the 
development of automated predictive systems for disease monitoring and continuous response 
evaluation.
Significance—Automated measurement and monitoring of therapeutic response is critical not 
only for objective evaluation of disease status prognosis but also for timely assessment of 
treatment strategies.
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I. Introduction
Acute myeloid leukemia (AML) is a malignant disease affecting both children and adults, 
with an age-adjusted incidence of 3.51 per 100,000 men and women per year in the United 
States (from 1975 to 2011). Although the 5-year relative survival rate has significantly 
improved since the 1970s, only 26% of patients diagnosed with AML will survive 5 years 
after diagnosis. For elderly patients (65+) the 5-year survival rate remains less than 6% [1].
Flow cytometry (FC) is a leading technology for cell analysis, allowing rapid evaluation of 
heterogeneous cellular populations in a single-cell setting; i.e., FC separately interrogates 
every individual cell. The analysis process uses fluorescently labeled antibodies to tag 
cellular epitopes known from their association with a specific cell lineage, function, or state. 
In combination with various probes for cell viability, structure, and function this 
methodology can provide information-rich data sets describing the phenotypic effects of 
various natural physiological phenomena or the impact of external perturbants on 
characteristics of cell populations [2].
Following the endorsement of the Bethesda International Consensus Group, as well as the 
guidance for classification of hematolymphoid neoplasms introduced by the 4th edition of 
the The World Health Organization’s Classification of Tumours of Haematopoietic and 
Lymphoid Tissues, FC immunophenotyping became a standard tool for AML diagnosis and 
disease monitoring [3], [4], [5]. FC is universally recognized as the method of choice for 
determining the blast lineage as well as for detecting aberrant antigenic phenotypic profiles 
[6], [7]. Although molecular classification has become a new standard for disease evaluation 
in AML, FC immunophenotypic characterization remains crucial for early staging of the 
disease, monitoring response to therapy, detecting minimal residual disease (MRD), and 
tracking relapse or progression [4], [8]. FC evaluation of AML has been demonstrated to be 
highly correlated with event-free survival (time to induction failure, relapse, secondary 
malignancy, or death), in contrast to the only very limited prognostic value offered by 
morphologic studies or PCR results [9], [10].
Evaluation of response to chemotherapy and assessment of disease progression are essential 
tasks in the management of patients with AML. With the advent of personalized medicine 
and the increasing use of targeted therapies whose activity depends upon the sustained 
expression of surface markers identified by FC, the use of clinical-decision support systems 
implemented as software support in co-developed companion diagnostic devices will be 
absolutely necessary [11], [12].
Although FC has been demonstrated by a number of reports to be more predictive and 
consistent than the alternatives, practitioners acknowledge that the reported results of FC-
based diagnostics depend strongly on correct interpretation of the highly complex raw FC 
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results. Indeed, the current approach to FC data analysis involves a painstaking interactive 
process of manually building long chains of gates by drawing them on the screen of a 
computer terminal with the help of a pointing device. The quality of the process depends 
immensely on the judgment and experience of the operator. Additionally, the process is hard 
to generalize, standardize, and transfer between laboratories or even between FC instruments 
designed by different manufacturers. Although the biological reasoning behind gating 
strategies is well established, the praxis of manual analysis remains difficult, time 
consuming, highly operator-dependent, costly, and hard to implement in new environments.
Ever since automated data analysis, machine learning, and bioinformatics began to establish 
themselves in the field of cytometry [13], [14], [15], the FC community has been trying to 
address these issues by proposing a number of diverse semiautomated algorithms that first 
pre-process the data by spectral unmixing (compensation) and then mimic the gating process 
with the help of a number of clustering techniques [15], [16], [17], [18], [19]. Although an 
increasing number of published computer-science methods leave no doubt that significant 
progress has been made in incorporating these techniques into analytical research pipelines, 
computational cytometry so far has had little or no impact on the clinical field. We 
hypothesize two principal reasons for that. First, even though the proposed algorithms 
automate the feature-extraction process, translating the raw cytometry data into vectors of 
cell-type proportions, the logic of these processes (the algorithm design) is ultimately driven 
by the experience of the operators (domain knowledge) and by their expectations regarding 
the data, rather than by the data alone. Therefore, the use of automated FC analysis often 
simply shifts the point of operator input within the analysis pipeline, rather than utilizing 
purely data-driven approaches. Second, the implemented machine-learning (ML) techniques 
typically frame the problem as a binary classification in which the patients are considered 
either “healthy” or “sick.” In fact, that was the framework of the FlowCAP competition, in 
which members of the computational cytometry community tested their solutions for 
automated AML classification [15]. However, as we argued before, such a setting is far from 
realistic. AML comprises a heterogeneous group of clonal neoplasms that differ 
substantially in cause, age of onset, clinical features, and prognosis. The changes during the 
progression of the disease, the presence of MRD, or the appearance of previously 
unobserved leukemia-associated phenotypes (LAPs) make FC classification of AML a more 
complex machine-learning problem.
Therefore, because of the tremendous diversity in the disease-associated phenotypes in 
AML, the computer-assisted approaches that perform well with one data set may not 
demonstrate such success in a clinical setting owing to the bias of the classifiers. We have 
already shown that a novel solution using a one-class classifier paired with non-parametric 
Bayesian models incorporating random effects can surpass traditional ML techniques when 
exposed to more challenging scenarios [20].
Herein, we report a solution to a complementary problem in automated classification - 
limited access to “normal” phenotypes. The traditional supervised methodology for 2-class 
classification operates under an assumption that both classes are well defined and that there 
is a certain level of homogeneity of the features within a class. As mentioned before, the 
diversity of AML renders this assumption invalid in relation to the characteristics of the 
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diseased class. We argued before that this problem can be addressed using a framework in 
which the diseased state is defined as a departure from normality [20].
Computational biologists often face an opposite dilemma. Although over a long period of 
time the researchers may successfully acquire a sufficiently diverse data set of abnormal 
cases representing well the complex landscape of a studied disease, access to “normal” 
samples may remain limited owing to prohibitive costs of sample collection, inconvenience, 
or ethical boundaries of research on healthy subjects. Often this problem is solved in an ad 
hoc manner by reusing samples representing unrelated diseases as approximately “normal.” 
In certain areas the problem of a small number of training samples can also be addressed in 
silico by using tools such as data augmentation.
In this report we also employ these strategies of using related biological data sets to define a 
“non-diseased” phenotype, in order to predict the direction of change and patient prognosis. 
The first classifier uses peripheral blood samples, which are labeled using a panel identical 
to that used for AML bone-marrow samples. The second classifier uses bone marrow data 
from patients diagnosed with lymphoma. Although the multidimensional point cloud defined 
by these samples does not represent a “normal” phenotype of bone marrow, it provides a 
direct contrast to an abnormal AML phenotype. Therefore, these cohorts of samples can be 
designated as “non-diseased” or “non-AML” for the purpose of classification.
The pooled diverse-diseased and non-diseased data are processed jointly using our 
previously demonstrated Bayesian modeling algorithm, ASPIRE [20]. The overall 
philosophy of this technique fundamentally differs from that of the methodology used in 
both traditional manual and most automated FC algorithms. First, ASPIRE does not employ 
any domain knowledge-based assumptions regarding the presence or frequency of particular 
leukemia-associated phenotypes (LAPs). We are aware that the diversity of the disease and 
the inherent noise in data covering a period of several years can make any approaches based 
on a carefully drafted set of steps in a decision tree-like arrangement impractical and highly 
dependent on the available training data. Instead, ASPIRE deduces the multidimensional 
arrangement of the data point cloud forming clusters and meta-clusters in the feature space. 
This is achieved by employing a non-parametric Bayesian (NPB) model as a core method in 
ASPIRE. The main building block of the algorithm is the highly flexible infinite mixture of 
infinite Gaussian mixtures (I2GMM) [21]. Unlike traditional mixture modeling, which 
requires information about the possible number of clusters (relevant biological populations, 
in this case) in advance, ASPIRE predicts the most probable number of relevant cell 
populations in a heterogeneous sample while simultaneously performing model inference 
and assessing the proportion of cells in each of these populations. Once the distributions of 
cell populations are estimated on the training data set by ASPIRE, individual cell data on 
both training and testing cases are classified using the recovered distributions to obtain 
phenotype vectors characterizing data for each patient at each time point. Then, training 
phenotype vectors are used for training a logistic regression classifier which is validated on 
the test set by analyzing the change in probability values corresponding to phenotype vectors 
of the same patient obtained at different time points. Data collection and methods are 
presented in Section II. Results are discussed in Section III.
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II. Materials and Methods
A. Data Collection
The study was approved by the Institutional Review Board of the Roswell Park Cancer 
Institute (IRB# BDR0517). The initial training set of healthy-donor blood samples (n=100) 
and patient bone-marrow samples (n=100) obtained at time of diagnosis were collected in 
sodium heparin and processed by the flow cytometry laboratory within 24 hours. The second 
set of model-validation samples were obtained from patients at time of diagnosis, post-
induction 1 (mean day 48.5; range 26–84) and post-induction 2 (approximately 1 year post 
induction, mean day 293.6; range 76–731). The post-induction 2 time point is available only 
for the relapse cases.
Blood and bone marrow were stained, acquired, and prepared for flow cytometric analysis as 
previously described [22]. Briefly, bone-marrow samples were first passed through a 35-
micron sieve to exclude spicules; then both blood and bone marrow were washed once with 
PBS containing heparin (10 units/mL) and then twice with FCM buffer (0.5% BSA, 0.004% 
Na2EDTA and 0.1% sodium azide prepared in PBS, pH 7.2). Cells were resuspended to their 
original volume in FCM buffer and incubated with normal mouse IgG (10μg/test) for 10 min 
to block FC receptors. Next, washed cells were aliquoted into tubes and stained with 
saturating amounts of the 4-color monoclonal antibody (mAb) cocktails described in Table 
1. The cells were incubated in the dark at ambient temperature for 20 minutes. After this 
incubation, red blood cells were lysed with BD FACSLyse (BD Bioscience, San Jose, CA) 
washed once with FCM buffer, and then fixed in 0.5% methanol-free formaldehyde 
(Polysciences, Warrington, PA). Samples were stored in the dark at 4 °C no longer than 24 
hours until analysis. Cytofluorometric analysis was performed using an unmodified 
FACSCalibur (BD BioSciences) flow cytometer and conventional data analysis was 
performed using WinList (Verity Software House, Topsham, ME).
B. FC Measurement Data Structure
Each patient sample or panel obtained at a given time point was subdivided into 7 tubes and 
analyzed with different mAb combinations using 4 mAbs per tube. Marker combinations for 
each tube are shown in Table I. In addition to four fluorescence-intensity values, the 
measurement also provides small-angle and large-angle light-scatter characteristics. 
Therefore, FC data obtained for each tube contained information for 20,000 – 50,000 cells, 
each represented by six parameters. Data obtained from each subject at a given time point 
contained seven data matrices of similar sizes, one for each tube, to be analyzed for 
phenotypic characterization.
C. Phenotypic Characterization for Training Cases
For identifying functionally distinct cell types across all FC data matrices in the training 
cohort (diseased and non-diseased samples) ASPIRE algorithm is used [20]. ASPIRE 
assumes each FC data matrix is generated by a global latent mixture model with potentially 
infinitely many components. The data in each FC matrix are generated from a specific subset 
of components in this mixture model. A component can also be understood as a global 
cluster each representing potentially functionally distinct cell types; local clusters are their 
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realizations in individual FC measurements. In other words, a metacluster represents a 
generalization of a specific cellular phenotype, whereas a cluster is a group of cells in a 
particular sample belonging to this immunophenotype.
The Dirichlet-process mixture model (DPM) is the building block of our data model. A 
DPM is a mixture model with a Dirichlet-process (DP) prior defined over mixture 
components [23]. DPM belongs to a group of non-parametric Bayesian models. It is non-
parametric because the number of clusters can arbitrarily grow to better accommodate data 
as needed. One of the two parameters of a DP prior, also known as the concentration 
parameter, controls the prior probability of producing a new component and thus indirectly 
controls the total number of components produced. The second parameter – the base 
distribution – defines the Bayesian aspect of DPM. In the case of Gaussian components one 
can utilize the base distribution to encode the existing knowledge of the domain by defining 
prior distributions over the mean vectors and covariance matrices of components.
In ASPIRE each FC data matrix is modeled by the infinite mixture of Dirichlet-process 
Gaussian-mixture models [21]. Model learning, which is performed in a single unified 
process, involves three main tasks: recovering local DPMs, finding global cluster 
associations of DPMs, and identifying the total number of clusters and their proportions in 
each FC measurement. The infinite mixture of DPMs, also known as the infinite mixture of 
infinitely many Gaussian mixture models (I2GMM), which is considered as a two-layer 
Gaussian mixture with an arbitrarily large number of components in each layer, offers 
extreme flexibility in modeling data sets with skewed and multi-mode cluster distributions. 
The lower layer estimates the density of the overall data set by clustering individual data 
points to components, while the upper layer associates components with clusters to allow for 
cluster recovery. As local distributions of a cell type in each FC measurement are noisy 
realizations of the true class distribution, i.e., a global meta-cluster, we introduce a sharing 
mechanism to create dependencies across DPMs associated with the same cell type. This is 
achieved by centering the base distributions of DPMs associated with the same cell type 
across FC measurements on a unique global parameter, which itself is distributed according 
to a higher-level DPM. This global DPM not only associates local distributions of a global 
cluster with one another but also models the number and proportions of clusters in each FC 
data matrix. We use a collapsed Gibbs sampler to perform inference [20].
This two-layer non-parametric model of Gaussian mixtures is ideally suited for identifying 
cell types in a FC data cohort for the following reasons. As a non-parametric model it 
addresses sample variability resulting in multi-mode and skewed cluster distributions by 
employing mixture models with arbitrarily large number of components. As a hierarchical 
model it allows for information sharing within as well as between samples, facilitating the 
discovery of rare populations. As a Bayesian approach, through use of prior distributions 
over cluster parameters, it makes possible the direct incorporation of domain knowledge 
about certain cell types into the model.
The generative model that encompasses these intricacies is described next.
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(1)
We denote each data point i of cluster k in FC data matrix j by xjki ∈ ℜd, where i = {1,…, 
njk}, k = {1, …, K}, and j = {1, …, J}, njk is the number of points from cluster k in data 
matrix j, K is the total number of global clusters identified, and J is the total number of data 
matrices. We use ϕk and θjki to define parameters of global clusters and their local 
realizations in each data matrix, respectively. The parameters α and γ adjust the prior 
probability of creating a local and global clusters, respectively.
Both G0 and Gjk are random probability measures distributed independently and identically 
according to a Dirichlet process. They can be considered as a mixture distribution with 
infinitely many components with their parameters drawn from the base distribution of the 
Dirichlet process and their weights from a stick-breaking distribution [24]. The stick-
breaking distribution considers a unit-length stick that is broken according to a sample 
drawn from a Beta distribution. Unlike continuous distributions, the probability of drawing 
the sample twice from G0 and Gjk is not zero and is proportional to the weight of the 
corresponding component. Thus, both G0 and Gjk are considered discrete distributions and 
offer clustering properties.
The base distribution H of the global Dirichlet process (DP) prior is defined as follows.
(2)
where μ0 is the expected center of the global clusters and κ0 is a scaling constant that 
controls their dispersion with respect to this center. The parameter σ0 is a positive definite 
matrix that encodes our prior belief about the shape of the clusters. The parameter m is a 
scalar that is negatively correlated with the degrees of freedom. In other words, the larger the 
m, the less σ will deviate from the expected shape, and vice versa.
Individual DPMs associated with the same global cluster share the same ϕk across data 
matrices. The notation Fϕk indicates a distribution F centered at ϕk and defines global 
cluster–specific base distributions of individual DPMs. Although Fϕk is same for all DPMs 
associated with the same global cluster, local clusters in data matrices are generated i.i.d. 
given ϕk of corresponding DPMs. Thus, each local realization of a global cluster is modeled 
by a different DPM, allowing us to account for measurement variations in a systematic 
manner.
For the sake of simplicity and to preserve conjugacy we assume that the covariance matrices 
of all local clusters associated with the global cluster are identical and limit the susceptibility 
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of local clusters to noise with their mean vectors. More specifically, μjki ~ Gjk, σjki = σk, and 
Fϕk is defined as
(3)
Note that the covariance matrix of the base distribution Fϕk is a function of σk; hence 
conjugacy of the model is preserved. Conjugacy of the model is important since it enables us 
to implement a collapsed version of the Gibbs sampler. The scaling constant κ1 adjusts the 
degree of dispersion of local means from the corresponding global mean. Posterior inference 
for the proposed model in (1) is performed by iteratively sampling local-cluster indicator 
variables for individual data points and global-cluster indicator variables for local clusters as 
described in detail in [20].
FC data matrices obtained from all available subjects in the training cohort (diseased and 
non-diseased samples) for a given tube were pooled together and the ASPIRE algorithm was 
run to identify local and global clusters (metaclusters) in the multi-dimensional point cloud 
defined by these data. Once global clusters and their local realizations were identified, the 
subject data for a given tube were characterized by the proportions of cells belonging to 
global clusters in the corresponding FC measurement, thus producing a vector of proportion 
values, i.e., a phenotype vector, for each tube. Since ASPIRE is a stochastic algorithm, the 
results obtained may differ slightly between runs. To account for this expected variability we 
run ASPIRE five times and report results averaged over these five runs.
D. Phenotypic Characterization for Test Samples
For the data and noise models discussed in Section II-C the posterior predictive distribution 
of a global cluster can be obtained in the form a multivariate student-t distribution with three 
parameters. In the following discussion a sample refers to a single FC mesaurement, i.e., a 
data matrix with rows representing cells and columns representing FC parameters, a global 
cluster refers to a cell type, and a data point refers to a cell.
(4)
The location vector (μ̂), the scale matrix (σ̂), and the degrees of freedom (v) are redefined for 
a global cluster as follows. Location vector:
(5)
Scale matrix:
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(6)
Degrees of freedom:
(7)
where κ̄ is defined as in (8)
(8)
D.k. denotes the subset of cells sharing global cluster k across all samples, and x̄jkt and Ajkt 
are the sample mean and the scatter matrix for the local cluster t of global cluster k in 
sample j, respectively, njkt is the number of data points in the local cluster t of global cluster 
k in sample j, and Ak is the scatter matrix for the global cluster k. These statistics are defined 
as in (9).
(9)
After the distributions of global clusters are estimated during training, FC data matrices 
describing the test cases can be evaluated row-by-row using the posterior predictive 
distributions corresponding to global clusters. This results in a vector of posterior probability 
values with each value indicating the probability of a cell’s belonging to one of the 
recovered global clusters (distinct cell immunophenotypes). The phenotypic characterization 
of a test case for a given tube at a given time point is achieved by averaging these probability 
vectors over all cells to get a phenotype vector for each FC measurement.
E. Classifier Training and Testing
The phenotype vectors corresponding non-diseased and AML cases in the training cohort 
were used to train a binary logistic regression classifier. Subsequently the classifier was 
applied to the test cases (diseased cases pre- and post-induction) in the test cohorts, and the 
probability of each test case’s representing a phenotype similar to non-diseased was 
evaluated and recorded for all available time points. Additionally, leave-one-out probabilities 
for two hundred cases in the training cohort were also computed and recorded for use in 
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relative evaluation of test-case probabilities with respect to those of training cases. The 
LIBLINEAR package was used to train a L2-regularized logistic regression classifier [25].
III. Results
ASPIRE was previously evaluated for a one-class classification problem identifying AML 
cases as deviations from normal ones on the FlowCap II data set and extensive analysis 
comparing ASPIRE with several benchmark clustering techniques from the literature was 
reported with favorable results in [20].
In this study we target a more challenging clinical problem and further confirm the utility of 
ASPIRE in the clinical management of patients with AML by presenting results of a proof-
of-concept study in predicting the direction of change in disease progression. Two separate 
cohorts of AML cases were used. The first contained data from 26 patients measured at two 
time points: pre- (t0) and post-induction (t1). The second contained data from 10 patients 
who relapsed after treatment. Three time points are accessible for this group: pre-induction, 
post-induction t1, and post-induction t2. The consensus diagnosis reached by manual flow 
cytometry analysis, cytogenetics, and histopatology evaluation was considered to be the 
ground truth for the purpose of our system validation.
A. Use of peripheral blood samples as a contrasting non-AML population
The ASPIRE-generated phenotype vectors corresponding to 100 non-AML and 100 AML 
cases were used to train a logistic regression classifier. Leave-one-out probabilities for these 
two hundred cases were also computed and represented for visualization. For the test 
cohorts, the probability of a patient’s moving toward a non-AML phenotype at a given time 
point was evaluated by a logistic regression classifier using all available FC data for that 
patient (results from the seven-tube panel) processed by ASPIRE. A two-stage probabilistic 
evaluation was executed. In the first stage, evaluation was performed independently for each 
tube. In the second stage, phenotype vectors from all tubes were concatenated to form a 
higher-dimensional phenotype vector and evaluation was performed using these newly 
formed vectors.
For all cases in the first sub-cohort, when all tubes were considered, the increase in 
probability values from t0 (pre-induction time point) to t1 (post-induction time point) 
suggests that the proposed technique correctly identified the direction of disease progression 
for all twenty-six patients (Figure 1). When the same analysis was performed for individual 
tubes, results indicate that tubes 1, 2, 4, and 5 would be sufficient to correctly identify 
favorable disease progression for all patients tested (See Figures S1–S4 in the Supplement). 
Tubes 1 and 7 (Figure S5) yielded the largest change in the probability values from t0 to t1 
(mean=0.44). This is still lower than the mean change of 0.55 obtained by using all tubes, 
which suggests that using all markers jointly may offer additional insight that would not be 
available when tubes are assessed independently.
For the second sub-cohort (10 patients who suffered relapse) with all tubes considered, the 
increase in probability values from t0 to t1 indicates that the proposed technique again 
correctly identified the favorable initial response for all ten patients (Figure 2). This result 
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matches the conclusion of the manual analysis of FC data performed by the trained flow 
cytometrist, as well as the results of cytogenetic and histopathology evaluations. However, 
when the probability values from t1 to t2 are considered, the decrease in probability values 
for nine out of ten cases indicates occurrence of relapse. This was a correct determination - 
confirmed by expert analysis - for all but one case. The mean increase in probability values 
from t0 to t1 is 0.53, whereas the mean decrease in probability values from t1 to t2 is 0.30.
When the same analysis was performed for individual tubes, it was noted that tube 1 alone 
again correctly identified the direction of change in disease progression for all ten cases 
from t0 to t1 as well from as t1 to t2 (Figure S6). For tube 1 the mean increase in probability 
values from t0 to t1 was 0.50, whereas the mean decrease from t1 to t2 was 0.29. These 
values are very similar to those obtained with all tubes combined, as well as higher than all 
other tubes analyzed individually.
Investigating further the single case for which the change in the direction of disease 
progression did not match the expert analysis performed by a hemopathologist when data 
from all tubes are used, we determined that the case indeed was a difficult case from a 
diagnostic perspective: manual cytometry data analysis and cytogenetics identified the case 
as a relapse, whereas the histopathological analysis diagnosed this case as “in remission.”
B. Use of stage I lymphoma bone-marrow samples as a contrasting non-AML population
The ASPIRE-generated phenotype vectors corresponding to 49 stage I lymphoma cases and 
100 AML cases were used to train a logistic regression classifier. As before, leave-one-out 
probabilities for these 149 cases were computed and represented for visualization. For the 
test cohorts, the probability of a patient’s moving toward a non-diseased phenotype at a 
given time point was evaluated by a logistic regression classifier using all available FC data 
for that patient (results from the seven-tube panel) processed by ASPIRE. A two-stage 
probabilistic evaluation was executed. In the first stage, evaluation was performed 
independently for each tube. In the second stage, phenotype vectors from all tubes were 
concatenated to form a higher-dimensional phenotype vector and evaluation was performed 
using these newly formed vectors.
For all cases in the first sub-cohort, when all tubes were considered, the increase in 
probability values from t0 (pre-induction time point) to t1 (post-induction time point) 
suggests that the proposed technique correctly identified the direction of disease progression 
for all twenty-six patients (Figure 3). When the same analysis was performed for individual 
tubes, results indicate that tubes 2, 4, 5, 6, and 7 would be sufficient to correctly identify 
favorable disease progression for all patients tested (See the Suplemental Figures S7–S11). 
Tube 7 yielded the largest change in the probability values from t0 to t1 (mean=0.70). This is 
significantly higher than the mean change of 0.56 obtained by using all tubes as well as 
corresponding mean changes for the remaining six tubes for which the changes in the 
probability values from t0 to t1 are between 0.30 and 0.53.
For the second sub-cohort (10 patients who suffered relapse) with all tubes considered, the 
increase in probability values from t0 to t1 indicates that the proposed technique correctly 
identified the favorable initial response for all ten patients (Figure 4). This result matches the 
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conclusion of the manual analysis of FC data performed by the trained flow cytometrist, as 
well as the results of cytogenetic and histopathology evaluations. When the probability 
values from t1 to t2 are considered, the decrease in probability values for nine out ten cases 
indicates occurrence of relapse. This was a correct determination - confirmed by expert 
analysis - for all but one case. The mean increase in probability values from t0 to t1 is 0.53, 
whereas the mean decrease in probability values from t1 to t2 is 0.23.
When the same analysis was performed for individual tubes, it was noted that tube 5 alone 
correctly identified the direction of change in disease progression for all ten cases from t0 to 
t1 as well from as t1 to t2 (Figure S12). For tube 1 the mean increase in probability values 
from t0 to t1 was 0.36, whereas the mean decrease from t1 to t2 was 0.21. The mean increase 
in probability values from t0 to t1 is significantly lower than that obtained with all tubes 
combined (0.36 vs. 0.53). However, the mean decrease in probability values from t1 to t2 is 
comparable to that obtained with all tubes combined (0.21 vs. 0.23).
It is also interesting to note that the largest mean increase in probability values from t0 to t1 
(0.61) as well as the largest mean decrease in probability values from t1 to t2 (0.25) is 
achieved for tube 7 (Figure S13). However, tube 7 predicts a decrease in probability values 
from t0 to t1 for one of the ten cases and an increase in probability values from t1 to t2 for 
two of the cases.
Upon further investigation we found that the single case for which ASPIRE failed to predict 
a decrease in probability from t1 to t2 when stage I lymphoma samples are used as normal 
cases is not the same case ASPIRE failed to predict a decrease in probability from t1 to t2 
when blood samples were used as normal cases. However, for that specific case we have 
identified that the measurement at time t2 has an artifact as it contains between only 500 to 
1000 events across all seven tubes while all other measurements contain around 25,000 
events.
IV. Discussion
Even though a number of previous reports demonstrated ability to automatically distinguish 
between normal and AML bone-marrow samples using computer-aided cytometry, the 
literature does not provide examples of autonomous algorithms in which different points in 
disease progression are associated with a meaningful probabilistic output that can be 
interpreted as reporting the direction of change (improvement or relapse). Our research 
targets this important area, using an innovative and original machine-learning methodology 
custom-developed for analysis of hematological FC results. The previously published binary 
statistical models did not generate a lot of excitement among clinical cytometrists, as the 
task of distinguishing pre-induction AML from normal samples is relatively easy, especially 
if abundant, well-characterized training samples are available. Automated classification 
becomes significantly more difficult when the system must account for disease diversity as 
well as for the inevitable presence of technical noise due to small differences in sample 
preparation, instrument operation, and data collection practices. The bar is additionally 
raised if access to the training samples is limited. All these obstacles were present in the 
processed data: the diseased training cohort represented samples spanning several years, 
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accounting for both biological diversity and technical noise, and the non-diseased set did not 
represented actual healthy bone-marrow samples, but a proxy sample of contrasting 
phenotype. The ASPIRE algorithm specifically developed to handle samples suffering from 
random effects performed well, extracting key biological features from the training data set 
and arriving at informative generalizations about the cell populations present.
In the cytometry sense, our system does not mimic a trained operator using preconceived 
and a priori-known information about informative cell populations and LAPs, but rather 
attempts to summarize the structure of the data point cloud by capturing the essential 
characteristics of the observed immunophenotypes. To accomplish this, in the first step the 
algorithm uses all the available training FC data (diseased bone-marrow samples and 
constrasting healthy peripheral-blood or stage I lymphoma samples) without any labels. This 
essential pre-processing part allows ASPIRE to generate a summary of relevant biology in 
the presence of inevitable experimental noise without using any labels and group 
information. In the second step we frame the problem as either anomaly detection or an 
“enhanced” detection of abnormality decrease.
The key limitation of using the ASPIRE system and similar Bayesian approaches is the non-
deterministic output and computationally costly processing. Since ASPIRE relies on 
Markov-chain Monte-Carlo sampling techniques there could be slight variations between 
runs in terms of the number and size of global clusters discovered. To account for this 
variability, we run the algorithm multiple times and average results over multiple runs. This 
process raises the computational cost but fortunately is required only during the training 
phase, which is performed offline. The testing phase which is performed with cases blinded 
to the algorithm uses the global clusters discovered during training and involves assigning 
each cell in a FC sample to one of these global clusters. For a typical FC sample containing 
around 50,000 cells this deterministic classification can be performed with a run-time speed 
on the order of seconds and produces the same output in each repetition.
From the clinical FC perspective the important limitation of the demonstrated data-
processing pathway is its incompatibility with established biology-driven data interpretation, 
in which the classification of a biological sample can be directly related to the judgment 
regarding proportion of cells in particular gates. The creation of these informative gates is 
not purely data-driven but guided by the previous experiences of an analyst interpreting the 
fluorescence-signal distribution in the space of selected biological parameters. Although 
ASPIRE formulates generalizations of biological subpopulations and represents them as 
metaclusters, the current version does not suggest which populations are “important” and 
cannot predict whether these statistically relevant populations are indeed biologically 
significant. From the practical perspective the need for direct visual interpretation of the 
automatically generated cytometry data analysis may be overestimated, as the goal of these 
processes is not to alleviate the burden of manual analysis in the first place. However, if such 
a need indeed arises one can imagine the implementation of an inverse step in which the 
covariates identified as important by the classifier are a subject to an inverse transform and 
represented at the end of the process as cluster boundaries overlaid onto traditional 
cytometry biaxial dot plots.
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Regrettably, the relatively small cohort of patients used for the demonstration of the 
algorithm’s capability does not allow us to investigate in depth its sensitivity and specificity 
across numerous important factors, such as AML subtype, patient age and/or overall health 
status, gene or chromosome changes in the cells belonging to abnormal populations, or the 
possibility that the studied leukemia occurred as a result of treatment for another different 
cancer. These are all important variables for which we hope to control in our further studies. 
It is also important to remember that the training phase did not use true normal bone-marrow 
samples. Again, at this phase of research it is impossible to determine if this leads to a 
biased classifier, which may perform differently for certain subgroups of possible AML 
immunophenotypes.
The ASPIRE algorithm is publicly available and can be tested by other FC researchers 
involved in studies of AML, as well as by scientists working on other hematological 
neoplasms.
V. Conclusions
This study provides the first example of a functional prototype of an automated non-
parametric Bayesian clinical decision-support system that can not only recognize the 
difference between normal and abnormal samples, but most importantly also recognize the 
direction of change in disease progression on the basis of the FC bone-marrow data alone, 
without the need to supplement the data with morphology and/or genetic analysis. We 
believe that these results are an important first step for objective evaluation of disease status 
as well as for timely assessment of treatment strategies in the clinical management of AML 
patients.
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Fig. 1. 
Probabilities obtained by the peripheral blood-based logistic regression classifier using 
phenotype vectors extracted by the ASPIRE algorithm from all the assay tubes available for 
the first cohort. The semi-transparent red points indicate non-diseased training samples, the 
semi-transparent green points denote AML training samples. The measures of individual test 
patients are shown as solid grey and green points. The arrows indicate the direction of 
change (disease progression) in the space defined by the training data. The results indicate 
that all the patients demonstrated positive change after therapy induction. The results match 
the known ground truth, as this patient sub-cohort responded well to therapy and 
subsequently recovered.
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Fig. 2. 
Probabilities obtained by the peripheral blood-based logistic regression classifier using 
phenotype vectors extracted by the ASPIRE algorithm from all the assay tubes for the 
second cohort. The measures of individual patients are shown as solid grey (pre-induction, 
t0), green (post induction, t1), and magenta points (post induction, t2). The arrows indicating 
the direction of change in disease progression indicate that all but one patient demonstrated 
signs of relapse after initial positive response to the therapy (data point circled with a blue 
dotted line).
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Fig. 3. 
Probabilities obtained by the lymphoma-based logistic regression classifier using phenotype 
vectors extracted by the ASPIRE algorithm from all the assay tubes available for the first 
cohort.
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Fig. 4. 
Probabilities obtained by the lymphoma-based logistic regression classifier using phenotype 
vectors extracted by the ASPIRE algorithm from all the assay tubes for the second cohort.
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